PEACE

Treatment tested

• Ocrelizumab

Inclusion: 1. Diagnosis of RRMS according to the 2017 or 2024 revised McDonald criteria 2. Age 18 years or older 3. Initiation of ocrelizumab SC planned by the healthcare professional (either as a switch from specific prior therapies or in treatment-naïve patients) 4. Physically and cognitively able to complete the study questionnaires and tests 5. Possession of a smartphone, tablet, or computer with an internet connection 6. Non-opposition to participation and data processing Exclusion: 1. Administration of ocrelizumab SC not in accordance with the standard of care or the current Summary of Product Characteristics (SmPC). 2. Patient under guardianship or judicial protection.

Background and study aims Multiple sclerosis (MS) can significantly impact a patient's autonomy and quality of life. This study, called PEACE, observes patients with Relapsing-Remitting MS (RRMS) who are starting a new treatment formulation: ocrelizumab injected subcutaneously (under the skin). The main aim is to understand how this treatment affects patients' satisfaction, autonomy, and daily symptoms in a real-world setting. Who can participate? Patients aged 18 years and over diagnosed with RRMS in France for whom their doctor has decided to prescribe subcutaneous ocrelizumab. What does the study involve? Participants will follow their standard medical care. In addition, they will complete questionnaires on a smartphone or computer about their quality of life, symptoms, and treatment satisfaction before their first injection and then every 6 months for 2 years. What are the possible benefits and risks of participating? As this is an observational study where patients receive standard care prescribed by their doctor, there are no additional medical risks associated with the study itself. There is no direct benefit, but participation helps improve understanding of MS treatments. Where is the study run from? Roche (France) When is the study starting and how long is it expected to run for? February 2026 to February 2029 Who is funding the study? Roche (France) Who is the main contact? Dr David Pau, david.pau@roche.com